Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer
Portfolio Pulse from
Eli Lilly's investigational drug, Imlunestrant, shows significant improvement in progression-free survival for ER+, HER2- advanced breast cancer patients, both as monotherapy and in combination with Verzenio. The Phase 3 EMBER-3 study results were published in the New England Journal of Medicine.
December 11, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's Imlunestrant significantly improves progression-free survival in advanced breast cancer patients, potentially boosting the company's oncology portfolio and stock performance.
The positive results from the Phase 3 EMBER-3 study of Imlunestrant, showing significant improvement in progression-free survival, are likely to enhance Eli Lilly's oncology portfolio. This could lead to increased investor confidence and a potential rise in LLY's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100